BCRX - BioCryst Pharmaceuticals, Inc.
| Previous close | 2.0500 |
| Open | 2.1100 |
| Bid | 1.9600 x 1800 |
| Ask | 1.9700 x 1000 |
| Day's range | 1.9100 - 2.1500 |
| 52-week range | 1.3800 - 8.8900 |
| Volume | 3,561,431 |
| Avg. volume | 5,643,671 |
| Market cap | 299.903M |
| Beta (5Y monthly) | 1.96 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.9420 |
| Earnings date | 05 May 2020 - 10 May 2020 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.13 |
- Zacks
BioCryst Sees Hammer Chart Pattern: Time to Buy?
BioCryst Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.
- Zacks
The Zacks Analyst Blog Highlights: AcelRx, BioCryst, Build-A-Bear, CACI and Evercore
The Zacks Analyst Blog Highlights: AcelRx, BioCryst, Build-A-Bear, CACI and Evercore
- Zacks
After a Brutal Q1, Q2 Gives a Ray of Hope: 5 Must Buys
After the Dow sees a quarter as ugly as this year's first quarter, the 124-year old index on average returns 11.8% in the following quarter. There is similar positive trend for the S&P 500 as well.
- Simply Wall St.
Here's Why BioCryst Pharmaceuticals (NASDAQ:BCRX) Can Manage Its Debt Despite Losing Money
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
- Zacks
BioCryst (BCRX) Upgraded to Strong Buy: Here's Why
BioCryst (BCRX) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Zacks
Implied Volatility Surging for BioCryst (BCRX) Stock Options
Investors need to pay close attention to BioCryst (BCRX) stock based on the movements in the options market lately.
- Zacks
BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates
BioCryst (BCRX) delivered earnings and revenue surprises of 92.00% and 230.49%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
BioCryst Pharmaceuticals (BCRX) in Focus: Stock Moves 8.5% Higher
BioCryst Pharmaceuticals (BCRX) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
- Zacks
Will BioCryst Pharmaceuticals (BCRX) Report Negative Earnings Next Week? What You Should Know
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
How Many BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Did Insiders Buy, In The Last Year?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
- Zacks
Is the Options Market Predicting a Spike in BioCryst (BCRX) Stock?
Investors need to pay close attention to BioCryst (BCRX) stock based on the movements in the options market lately.
- Zacks
BioCryst Submits NDA for Hereditary Angioedema Candidate
BioCryst (BCRX) files a new drug application to the FDA for once-daily berotralstat (BCX7353), which is being developed for the prevention of hereditary angioedema attacks.
- Simply Wall St.
Imagine Owning BioCryst Pharmaceuticals (NASDAQ:BCRX) And Trying To Stomach The 80% Share Price Drop
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We don't wish...
- Zacks
BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Lags Revenue Estimates
BioCryst (BCRX) delivered earnings and revenue surprises of -9.68% and -60.92%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Analysts Estimate BioCryst Pharmaceuticals (BCRX) to Report a Decline in Earnings: What to Look Out for
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Motley FoolBiocryst Pharmaceuticals Inc (BCRX) Q2 2019 Earnings Call Transcript
BCRX earnings call for the period ending June 30, 2019.
- Zacks
BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Lags Revenue Estimates
BioCryst (BCRX) delivered earnings and revenue surprises of -9.68% and -42.43%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Earnings Preview: BioCryst Pharmaceuticals (BCRX) Q2 Earnings Expected to Decline
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Motley Fool
Here's Why BioCryst Pharmaceuticals Is Soaring Today
A hedge fund disclosed a sizable stake in the company.
- Motley Fool
Why J.C. Penney, Mallinckrodt, and BioCryst Pharmaceuticals Slumped Today
Tough conditions for these companies left them out of the day's rally.
